Large gap with delayed quotes
|
Last quote
04/27/2026
-
19:12:45
|
Bid
04/27/2026 -
19:14:28
|
Bid Volume |
Ask
04/27/2026 -
19:14:28
|
Ask Volume |
|---|---|---|---|---|
|
74.25
+0.34
(
+0.46% )
|
74.18
|
200 |
74.30
|
200 |
Analysis date: 24.04.2026
Global Evaluation
Slightly negative
Slightly negative
The stock is classified in the slightly negative zone since 07.04.2026.
Interest
Weak
Weak
Two stars since 07.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 13.02.2026 at a price of 63.82.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 31.03.2026.
4wk Rel Perf
22.07%
22.07%
The four-week dividend-adjusted overperformance versus SP500 is 22.07%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.24%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.52%.
Mkt Cap in $bn
10.35
10.35
With a market capitalization >$8bn, ARROWHEAD PHARMA is considered a large-cap stock.
G/PE Ratio
-1.13
-1.13
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-23.74
-23.74
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-26.77%
-26.77%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
10
10
Over the last seven weeks, an average of 10 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
221
221
For 1% of index variation, the stock varies on average by 2.21%.
Correlation
0.44
0.44
43.86% of stock movements are explained by index variations.
Value at Risk
44.80
44.80
The value at risk is estimated at USD 44.80. The risk is therefore 60.62%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
11.09.2020
11.09.2020